Tags

Type your tag names separated by a space and hit enter

Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30; 31(2):383-8.PN

Abstract

PURPOSE

This study evaluated changes in weight, glucose and lipid metabolism in patients with schizophrenia and antipsychotic-related metabolic disturbances who were switched to ziprasidone.

METHODS

Eighty-four outpatients with schizophrenia or schizoaffective disorder also having glucose intolerance, diabetes, dyslipidemia or weight gain related to their antipsychotic treatment were switched to ziprasidone. Clinical status was assessed using the Clinical Global Impression of Severity (CGI-S) and Improvement (CGI-I) scales and the Positive and Negative Syndrome Scale (PANSS). Assessment scales, weight, glucose and lipids were measured at baseline and at three and six months of ziprasidone treatment.

RESULTS

Significant baseline to endpoint reductions were seen in mean weight (-5.1 kg), Body Mass Index (BMI; -1.6 kg/m(2)), serum glucose (-14.0 mg/dL), total cholesterol (-24.1 mg/dL), and triglyceride leves (-46.2 mg/dL). Mean PANSS total score improved 13.9% after 6 months of treatment with ziprasidone. A proportion (34.3%) of patients were classified as much improved in the CGI-I.

CONCLUSIONS

Switching patients with schizophrenia to ziprasidone when metabolic disturbances are detected may improve these side effects and result in an improved overall outcome.

Authors+Show Affiliations

CSM Fuenlabrada, Avenida de la Comunidad de Madrid 10, Fuenlabrada 28945, Madrid, Spain. j_m_montes@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Evaluation Study
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17129654

Citation

Montes, José Manuel, et al. "Improvement in Antipsychotic-related Metabolic Disturbances in Patients With Schizophrenia Switched to Ziprasidone." Progress in Neuro-psychopharmacology & Biological Psychiatry, vol. 31, no. 2, 2007, pp. 383-8.
Montes JM, Rodriguez JL, Balbo E, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(2):383-8.
Montes, J. M., Rodriguez, J. L., Balbo, E., Sopelana, P., Martin, E., Soto, J. A., Delgado, J. F., Diez, T., & Villardaga, I. (2007). Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Progress in Neuro-psychopharmacology & Biological Psychiatry, 31(2), 383-8.
Montes JM, et al. Improvement in Antipsychotic-related Metabolic Disturbances in Patients With Schizophrenia Switched to Ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):383-8. PubMed PMID: 17129654.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. AU - Montes,José Manuel, AU - Rodriguez,Jose Luis, AU - Balbo,Eduardo, AU - Sopelana,Pedro, AU - Martin,Eloy, AU - Soto,Jose Antonio, AU - Delgado,Jose Francisco, AU - Diez,Teresa, AU - Villardaga,Inmaculada, Y1 - 2006/11/28/ PY - 2006/05/23/received PY - 2006/10/03/revised PY - 2006/10/03/accepted PY - 2006/11/30/pubmed PY - 2007/4/25/medline PY - 2006/11/30/entrez SP - 383 EP - 8 JF - Progress in neuro-psychopharmacology & biological psychiatry JO - Prog Neuropsychopharmacol Biol Psychiatry VL - 31 IS - 2 N2 - PURPOSE: This study evaluated changes in weight, glucose and lipid metabolism in patients with schizophrenia and antipsychotic-related metabolic disturbances who were switched to ziprasidone. METHODS: Eighty-four outpatients with schizophrenia or schizoaffective disorder also having glucose intolerance, diabetes, dyslipidemia or weight gain related to their antipsychotic treatment were switched to ziprasidone. Clinical status was assessed using the Clinical Global Impression of Severity (CGI-S) and Improvement (CGI-I) scales and the Positive and Negative Syndrome Scale (PANSS). Assessment scales, weight, glucose and lipids were measured at baseline and at three and six months of ziprasidone treatment. RESULTS: Significant baseline to endpoint reductions were seen in mean weight (-5.1 kg), Body Mass Index (BMI; -1.6 kg/m(2)), serum glucose (-14.0 mg/dL), total cholesterol (-24.1 mg/dL), and triglyceride leves (-46.2 mg/dL). Mean PANSS total score improved 13.9% after 6 months of treatment with ziprasidone. A proportion (34.3%) of patients were classified as much improved in the CGI-I. CONCLUSIONS: Switching patients with schizophrenia to ziprasidone when metabolic disturbances are detected may improve these side effects and result in an improved overall outcome. SN - 0278-5846 UR - https://www.unboundmedicine.com/medline/citation/17129654/Improvement_in_antipsychotic_related_metabolic_disturbances_in_patients_with_schizophrenia_switched_to_ziprasidone_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0278-5846(06)00358-7 DB - PRIME DP - Unbound Medicine ER -